{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-043519","form_type":"8-K","ticker":"CERO","cik":"0001870404","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2026-04-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.193727+00:00","generated_at":"2026-05-15T06:26:36.779091+00:00","sec_items":["1.01","2.03","3.02","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"CERo Therapeutics issues $437,500 convertible note to Keystone Capital Partners, 10% interest, due 2027","bullets":["Issued to Keystone Capital Partners a convertible note with purchase price $350,000 and face value $437,500.","Note bears interest at 10% per annum, matures April 9, 2027, with up to $1,000,000 total borrowing capacity.","Conversion price is lesser of $0.05 or 80% of avg of 5 lowest intraday prices in 20 days prior to conversion.","Beneficial ownership limitation of 4.99% applies; issuance exempt from registration under Section 4(a)(2)."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-043519","json":"https://secwatch.observer/filing/0001213900-26-043519.json","markdown":"https://secwatch.observer/filing/0001213900-26-043519.md","text":"https://secwatch.observer/filing/0001213900-26-043519.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1870404/000121390026043519/0001213900-26-043519-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1870404/000121390026043519/ea0286319-8k_cero.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T06:26:36.779091+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"083c34068eaf5086b053e6f1624e0c355fd070ce","claim":"CERO THERAPEUTICS HOLDINGS, INC. incurred convertible notes of $350,000 with Keystone Capital Partners, LLC at 10% per annum maturing April 9, 2027.","evidence_excerpt":"On April 8, 2026, CERo Therapeutics Holdings, Inc., a Delaware corporation (the “Company”) issued and sold a convertible promissory note for an purchase price of $350,000, having a principal face value of $437,500 (the “Note”) to Keystone Capital Partners, LLC (“Lender”).","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390026043519/0001213900-26-043519-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"convertible notes"},{"label":"Principal","value":"$350,000"},{"label":"Counterparty","value":"Keystone Capital Partners, LLC"},{"label":"Rate","value":"10% per annum"},{"label":"Maturity","value":"April 9, 2027"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"},{"claim_id":"cadd08f3e3d9459f379d7808a1c384750d69057e","claim":"CERO THERAPEUTICS HOLDINGS, INC. issued convertible note to Keystone Capital Partners, LLC for purchase price of $350,000.","evidence_excerpt":"On April 8, 2026, CERo Therapeutics Holdings, Inc., a Delaware corporation (the “Company”) issued and sold a convertible promissory note for an purchase price of $350,000, having a principal face value of $437,500 (the “Note”) to Keystone Capital Partners, LLC (“Lender”).","evidence_source":"SEC 8-K Item 3.02/3.03","evidence_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390026043519/0001213900-26-043519-index.htm","confidence":0.9,"family_label":"Equity Issuances","details":[{"label":"Security","value":"convertible note"},{"label":"Purchaser","value":"Keystone Capital Partners, LLC"},{"label":"Consideration","value":"purchase price of $350,000"}],"fact_type":"equity_issuance"},{"claim_id":"2d2188ed3529d5b0fe8db50a869c555d5ecfd5c0","claim":"CERO THERAPEUTICS HOLDINGS, INC. entered into Note with Keystone Capital Partners, LLC valued at $350,000 (effective 2026-04-08).","evidence_excerpt":"On April 8, 2026, CERo Therapeutics Holdings, Inc., a Delaware corporation (the “Company”) issued and sold a convertible promissory note for an purchase price of $350,000, having a principal face value of $437,500 (the “Note”) to Keystone Capital Partners, LLC (“Lender”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390026043519/0001213900-26-043519-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"notes offering"},{"label":"Counterparty","value":"Keystone Capital Partners, LLC"},{"label":"Value","value":"$350,000"},{"label":"Effective","value":"2026-04-08"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}